Finally Time to Make a Move? H.C. Wainwright Initiates Coverage On Acceleron Pharma (NASDAQ:XLRN) with $57 Price Target

October 13, 2017 - By Vivian Park

 Finally Time to Make a Move? H.C. Wainwright Initiates Coverage On Acceleron Pharma (NASDAQ:XLRN) with $57 Price Target

Investors sentiment increased to 1.44 in Q2 2017. Its up 0.51, from 0.93 in 2017Q1. It is positive, as 16 investors sold Acceleron Pharma Inc shares while 27 reduced holdings. 17 funds opened positions while 45 raised stakes. 33.54 million shares or 7.21% more from 31.29 million shares in 2017Q1 were reported.

Sectoral Asset Management owns 2.01% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 604,499 shares. 120,000 are owned by Hudson Bay Mngmt L P. Westfield Management Lp invested in 0.44% or 1.68M shares. Sei Invs holds 0% or 300 shares in its portfolio. Pnc Fincl Services Grp holds 8,460 shares. Oppenheimer Asset Management Incorporated holds 0% or 837 shares. 1,861 were accumulated by Da Davidson & Co. Ghost Tree Capital Ltd Liability Com has invested 0.57% in Acceleron Pharma Inc (NASDAQ:XLRN). State Street holds 1.13M shares. Alps Inc has invested 0.01% in Acceleron Pharma Inc (NASDAQ:XLRN). Nationwide Fund has 24,737 shares for 0% of their portfolio. Lord Abbett Limited Liability Corp reported 0.01% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Tiaa Cref Inv Management Ltd Company holds 0% or 86,211 shares. Putnam Investments Lc, Massachusetts-based fund reported 30,014 shares. Jasper Ridge Prtn Ltd Partnership owns 12,498 shares.

Why Has H.C. Wainwright Given Acceleron Pharma (NASDAQ:XLRN) a $57 Price Target

H.C. Wainwright analyst initiated coverage with a Buy rating on Acceleron Pharma (NASDAQ:XLRN) today and set a price target of $57. The firm’s shares opened today at 0.

Investors sentiment increased to 1.44 in Q2 2017. Its up 0.51, from 0.93 in 2017Q1. It is positive, as 16 investors sold Acceleron Pharma Inc shares while 27 reduced holdings. 17 funds opened positions while 45 raised stakes. 33.54 million shares or 7.21% more from 31.29 million shares in 2017Q1 were reported.

Sectoral Asset Management owns 2.01% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 604,499 shares. 120,000 are owned by Hudson Bay Mngmt L P. Westfield Management Lp invested in 0.44% or 1.68M shares. Sei Invs holds 0% or 300 shares in its portfolio. Pnc Fincl Services Grp holds 8,460 shares. Oppenheimer Asset Management Incorporated holds 0% or 837 shares. 1,861 were accumulated by Da Davidson & Co. Ghost Tree Capital Ltd Liability Com has invested 0.57% in Acceleron Pharma Inc (NASDAQ:XLRN). State Street holds 1.13M shares. Alps Inc has invested 0.01% in Acceleron Pharma Inc (NASDAQ:XLRN). Nationwide Fund has 24,737 shares for 0% of their portfolio. Lord Abbett Limited Liability Corp reported 0.01% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Tiaa Cref Inv Management Ltd Company holds 0% or 86,211 shares. Putnam Investments Lc, Massachusetts-based fund reported 30,014 shares. Jasper Ridge Prtn Ltd Partnership owns 12,498 shares.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Acceleron Pharma has $63 highest and $20 lowest target. $42.57’s average target is 9.63% above currents $38.83 stock price. Acceleron Pharma had 32 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Outperform” rating by FBR Capital on Friday, January 15. As per Friday, October 6, the company rating was maintained by Piper Jaffray. The rating was initiated by Oppenheimer on Friday, November 20 with “Outperform”. Oppenheimer maintained Acceleron Pharma Inc (NASDAQ:XLRN) on Friday, June 23 with “Hold” rating. Barclays Capital maintained it with “Overweight” rating and $42 target in Monday, June 13 report. The stock has “Neutral” rating by Janney Capital on Thursday, December 17. FBR Capital maintained the stock with “Buy” rating in Tuesday, June 13 report. The firm has “Outperform” rating by FBR Capital given on Monday, January 18. The rating was initiated by Oppenheimer with “Outperform” on Tuesday, December 13. Citigroup initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, September 29 with “Neutral” rating.

The stock decreased 0.13% or $0.05 during the last trading session, reaching $38.83. About 190,342 shares traded. Acceleron Pharma Inc (NASDAQ:XLRN) has declined 22.43% since October 13, 2016 and is downtrending. It has underperformed by 39.13% the S&P500.

Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on November, 2. They expect $-0.68 earnings per share, down 23.64 % or $0.13 from last year’s $-0.55 per share. After $-0.77 actual earnings per share reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts -11.69 % EPS growth.

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.71 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. It currently has negative earnings. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta , protein superfamily.

More notable recent Acceleron Pharma Inc (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron’s Unique Pipeline Looks Undervalued” on October 12, 2017, also Streetinsider.com with their article: “Acceleron Pharma (XLRN) Plans $150M Offering of Common Stock” published on September 19, 2017, Streetinsider.com published: “Acceleron Pharma (XLRN) Prices 5.405M Common Share Offering at $37/Sh” on September 21, 2017. More interesting news about Acceleron Pharma Inc (NASDAQ:XLRN) were released by: Businesswire.com and their article: “Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares” published on October 05, 2017 as well as Benzinga.com‘s news article titled: “4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate” with publication date: October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.